IBM has reversed sharply from its 7% surge of the prior week, shedding nearly all of those gains in the days since — and options traders have quietly shifted into a more defensive posture ahead of October earnings.
The price move is the immediate story. IBM closed at $231.38 on Tuesday, down 6.8% on the week — erasing almost the entirety of the rally noted in last week's note. That prior article flagged fresh shorts re-entering into strength at $248; they've now been rewarded. The weakness is broadly sector-driven rather than IBM-specific, though IBM is far from immune. Close peers ACN and KD dropped 5% and 8.9% respectively on the week, while GLOB fell a sharper 12.7%. On the other side, MDB surged 13.2%, underscoring the bifurcated momentum running through technology services right now.
Short positioning has moved in the opposite direction from the previous week's rebuild. Short interest has eased roughly 3.2% over the past seven days to 2.2% of the free float — about 20.7 million shares — reversing some of the accumulation that had been flagged in last week's note. The lending market remains entirely frictionless: borrow availability has expanded dramatically, now running near 4,890% of outstanding short interest, a 33% increase over the week and a level that implies virtually no pressure on existing shorts and unlimited room for new ones. Cost to borrow has edged up about 43% on the week to 0.40%, but in absolute terms that remains one of the cheapest borrows in the large-cap technology universe. There is nothing in the lending market that would deter short sellers from adding further if the fundamental narrative deteriorates.
Options positioning has turned modestly more defensive. The put/call ratio has risen to 0.84, roughly 1.5 standard deviations above its 20-day average of 0.80. That reading is not extreme — the 52-week high is 1.05 — but the direction of travel matters: the PCR has climbed noticeably since mid-September, when it was tracking in the 0.77–0.78 range. With Q3 results due October 21, some of that demand for puts likely reflects hedging into the print rather than an outright directional bet. The last two earnings days produced moves of -1.8% and -0.4% on the day, followed by a strong five-day recovery of 7.6% after the July 2026 print — a pattern that has historically rewarded patience over speed.
The Street's stance is harder to read cleanly after a wave of post-July target cuts. Following IBM's Q2 report in late July, analysts across the board slashed price targets sharply — Morgan Stanley moved from $293 to $190, Barclays from $350 to $288 before subsequently cutting again to $262, and Susquehanna trimmed twice in quick succession, most recently raising its target to $235 at the end of August. The consensus remains a "buy" with a mean target of $240.59, implying roughly 4% upside from current levels — not a ringing endorsement for a stock trading 19% below where it began the year. EPS momentum factor scores rank in the bottom quartile of the universe, with 30-day and 90-day momentum readings of 27 and 23 respectively. The bull case rests on Red Hat and watsonx building durable software revenue streams; the bear case is the persistent hardware-company perception overhang and the question of whether AI consulting wins can offset client attrition elsewhere.
The ORTEX short score sits at 32, essentially flat over the past two weeks, suggesting no meaningful shift in the composite short signal despite the price volatility. What to watch into October 21 is whether the gap between the consensus target and the current price narrows through fresh analyst activity, or whether the post-July target reset is still digesting — and whether IBM can demonstrate that the Q2 softness was a one-quarter stumble rather than the start of a trend.
See the live data behind this article on ORTEX.
Open IBM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
